Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bupropion (Zyban) Clear all
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 1 Interventional Results available

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

NCT00285584
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Bupropion, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 2 Interventional Results available

Treating Negative Affect in Low Back Pain Patients

NCT04747314
View directory record Official record
Conditions
Chronic Low Back Pain, Negative Affectivity
Interventions
Antidepressant, Enhanced Fear Avoidance Rehabilitation
Drug · Other
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

NCT00567255
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 13, 2026, 7:40 AM EDT
Terminated Phase 4 Interventional

Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder

NCT00181896
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
bupropion SR
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2011 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

NCT01764386
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB, CLI, Usual Care
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

NCT00135785
View directory record Official record
Conditions
Methamphetamine
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 100 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05557409
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3

NCT00136786
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

NCT03047005
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 13, 2026, 7:40 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
varenicline (Chantix), bupropion (Zyban), nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 4 Interventional

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

NCT00917059
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 13, 2026, 7:40 AM EDT
Active, not recruiting Phase 3 Interventional

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

NCT03996265
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
542
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 7:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers

NCT01048944
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Bupropion SR, Nicotine Patch, Placebo Patch and Placebo Pill
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 4 Interventional Results available

Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers

NCT02245308
View directory record Official record
Conditions
Tobacco Use Disorder, Homelessness
Interventions
Nicotine Patches, mobile contingency management (mCM), Smoking cessation counseling, Nicotine rescue method, Bupropion
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 13, 2026, 7:40 AM EDT
Terminated Phase 2 Interventional Results available

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

NCT03132571
View directory record Official record
Conditions
Schizophrenia, Diabetes Mellitus, Type 2, Obesity
Interventions
Naltrexone, Bupropion, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

NCT01635972
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Bupropion, Healthy Volunteers
Interventions
Isavuconazole, bupropion hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions
AXS-05 (dextromethorphan and bupropion) oral tablets
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bupropion for Smoking Cessation in Pregnancy

NCT01875172
View directory record Official record
Conditions
Smoking Cessation, Pregnancy
Interventions
Bupropion SR, placebo, smoking cessation counseling
Drug · Behavioral
Lead sponsor
Watching Over Mothers & Babies Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Not applicable Interventional Results available

Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers

NCT01691105
View directory record Official record
Conditions
Tobacco Use Cessation, Smoking Cessation, Smoking, Tobacco Use Disorder
Interventions
AD + Integrated Tobacco Order Set
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 13, 2026, 7:40 AM EDT
Completed Phase 4 Interventional Results available

Bupropion for Smoking Cessation During Pregnancy

NCT01390246
View directory record Official record
Conditions
Pregnancy Related, Tobacco Use Disorder
Interventions
Bupropion SR, Smoking Cessation Counseling, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 13, 2026, 7:40 AM EDT
Not listed No phase listed Observational

Comparative Tobacco Interventions for Individuals With Severe and Persisting Behavioral Health Disorders

NCT04523948
View directory record Official record
Conditions
Tobacco Use
Interventions
Behavioral and pharmacological support to reduce combustible tobacco use.
Behavioral
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 13, 2026, 7:40 AM EDT